Detailed Information on Publication Record
2021
The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma
EID, Michal, Paraskevi KAROUSI, Lumír KUNOVSKÝ, Štěpán TUČEK, Dagmar BRANČÍKOVÁ et. al.Basic information
Original name
The Role of Circulating MicroRNAs in Patients with Early-Stage Pancreatic Adenocarcinoma
Authors
EID, Michal (203 Czech Republic, belonging to the institution), Paraskevi KAROUSI, Lumír KUNOVSKÝ (203 Czech Republic, belonging to the institution), Štěpán TUČEK (203 Czech Republic, belonging to the institution), Dagmar BRANČÍKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk KALA (203 Czech Republic, belonging to the institution), Ondřej SLABÝ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Christos K. KONTOS (guarantor) and Jan TRNA (203 Czech Republic, belonging to the institution)
Edition
Biomedicines, Basel, MDPI, 2021, 2227-9059
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10608 Biochemistry and molecular biology
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.757
RIV identification code
RIV/00216224:14110/21:00122646
Organization unit
Faculty of Medicine
UT WoS
000716958200001
Keywords in English
pancreatic cancer; early stage; microRNA; diagnosis; prognosis; chemoresistance
Tags
International impact, Reviewed
Změněno: 7/12/2021 13:36, Mgr. Tereza Miškechová
Abstract
V originále
Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is still associated with a high rate of mortality. Only a minority of patients are diagnosed in the early stage. Radical surgery is the only potential curative procedure. However, radicality is reached in 20% of patients operated on. Despite the multidisciplinary approach in resectable tumors, early tumor recurrences are common. Options on how to select optimal candidates for resection remain limited. Nevertheless, accumulating evidence shows an important role of circulating non-coding plasma and serum microRNAs (miRNAs), which physiologically regulate the function of a target protein. miRNAs also play a crucial role in carcinogenesis. In PDAC patients, the expression levels of certain miRNAs vary and may modulate the function of oncogenes or tumor suppressor genes. As they can be detected in a patient’s blood, they have the potential to become promising non-invasive diagnostic and prognostic biomarkers. Moreover, they may also serve as markers of chemoresistance. Thus, miRNAs could be useful for early and accurate diagnosis, prognostic stratification, and individual treatment planning. In this review, we summarize the latest findings on miRNAs in PDAC patients, focusing on their potential use in the early stage of the disease.
Links
MUNI/A/1595/2020, interní kód MU |
|